Novo Nordisk's CagriSema Study could potentially help patiend with Diabetic Neuropathy manage nerve pain. Read more on https: www.tipranks.com news company announcements novo nordisks cagrisema study a potential game changer for diabetic neuropathy Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial ScienceDirect CagriSema Dual Pathway Metabolic Signaling Compound CagriSema combines two investigational molecules Cagrilintide (amylin analogue) and Semaglutide (GLP 1 receptor agonist), designed to influence key metabolic and appetite regulating pathways. Current Novo Nordisk's next generation weight loss drug CagriSema matches Lilly's Zepbound in major trial, but doesn't surpass it CNN